DexCom has a well-established record of introducing the most precise sensors for use in its continuous glucose monitors. On the strength of its technology, DexCom has captured an impressive slice of ...
Predictions of a sales-growth slowdown sent DexCom stock tumbling this summer. Management predicted third-quarter sales would rise by just 1% to 3% year over year. Two of DexCom's top competitors ...
DexCom's stock has declined 35% since my last bearish article, validating my "Sell" rating, though past bearish calls were incorrect as the stock previously doubled and tripled. Q3 results showed ...
DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset, but management are optimistic about rebuilding BME sales channel. DexCom's newest G7 CGM competes closely ...
The world’s population is aging at an unprecedented pace. According to WHO’s October 2024 report, the number of people aged 60 and older surpassed children under five for the first time in 2020. By ...
While still a couple of years out, MD+DI gained some insights into Dexcom's next-generation sensor from an interview with the ...
This year started with healthy gains for DexCom (NASDAQ: DXCM) stock, but they didn't last long. The medical device stock is now down by about 53% from the high-water mark it set in April. DexCom ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results